|Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer|
H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ...
New England Journal of Medicine 373 (17), 1627-1639, 2015
|Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer|
NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ...
Science 348 (6230), 124-128, 2015
|Pembrolizumab for the treatment of non–small-cell lung cancer|
EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ...
New England Journal of Medicine 372 (21), 2018-2028, 2015
|Nivolumab plus ipilimumab in advanced melanoma|
JD Wolchok, H Kluger, MK Callahan, MA Postow, NA Rizvi, AM Lesokhin, ...
N Engl J Med 369, 122-133, 2013
|Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade|
N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ...
Science 351 (6280), 1463-1469, 2016
|Tumor mutational load predicts survival after immunotherapy across multiple cancer types|
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
|Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase …|
NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ...
The lancet oncology 16 (3), 257-265, 2015
|Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer|
SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ...
Journal of clinical oncology 33 (18), 2004, 2015
|Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non–small-cell lung cancer|
VA Miller, MG Kris, N Shah, J Patel, C Azzoli, J Gomez, LM Krug, W Pao, ...
Journal of Clinical Oncology 22 (6), 1103-1109, 2004
|Association of pembrolizumab with tumor response and survival among patients with advanced melanoma|
A Ribas, O Hamid, A Daud, FS Hodi, JD Wolchok, R Kefford, AM Joshua, ...
Jama 315 (15), 1600-1609, 2016
|Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib|
GJ Riely, W Pao, DK Pham, AR Li, N Rizvi, ES Venkatraman, ...
Clinical cancer research 12 (3), 839-844, 2006
|Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study|
MD Hellmann, NA Rizvi, JW Goldman, SN Gettinger, H Borghaei, ...
The lancet oncology 18 (1), 31-41, 2017
|Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy|
D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ...
Science 359 (6375), 582-587, 2018
|Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials …|
L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ...
Journal of clinical oncology 35 (35), 3924, 2017
|Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer|
MD Hellmann, MK Callahan, MM Awad, E Calvo, PA Ascierto, A Atmaca, ...
Cancer cell 33 (5), 853-861. e4, 2018
|Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study|
EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, ...
Journal of Clinical Oncology 37 (28), 2518, 2019
|Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study|
S Antonia, SB Goldberg, A Balmanoukian, JE Chaft, RE Sanborn, A Gupta, ...
The lancet oncology 17 (3), 299-308, 2016
|Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas|
A Drilon, L Wang, A Hasanovic, Y Suehara, D Lipson, P Stephens, J Ross, ...
Cancer discovery 3 (6), 630-635, 2013
|Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers|
AL Pecora, N Rizvi, GI Cohen, NJ Meropol, D Sterman, JL Marshall, ...
Journal of Clinical Oncology 20 (9), 2251-2266, 2002
|Classification of current anticancer immunotherapies|
L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ...
Oncotarget 5 (24), 12472, 2014